Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities (Merck Acquisition [Member], USD $)	0 Months Ended	3 Months Ended
	Nov. 15, 2013	Dec. 31, 2013
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		$ 55,700
Prepaid expenses		100
Deferred tax assets, net		700
Total fair value of acquired assets		56,500
Consideration paid	52,800,000	52,800
Gain from bargain purchase		3,700
AzaSite [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		13,800
Cosopt [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		21,600
Cosopt PF [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		$ 20,300